Therapeutics Companies in Europe

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

We are Bicycle Therapeutics, a clinical-stage biopharmaceutical company. We didn’t wait for the next advance against cancer. We created it. Based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesized medicines. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date. Bicycles can be used as Bicycle conjugates to deliver toxin payloads and to precisely target local immune activation within tumors and as Bicycle T-cell modulators, which activate cytotoxic T-cells while circumventing the limitations of antibody and biologic therapies and better enabling combination therapy. Our lead product candidate, BT1718, is a Bicycle toxin conjugate currently being investigated in a Phase I/IIa open label dose escalation and expansion clinical trial sponsored by Cancer Research UK. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14, which is highly expressed in many solid tumors. Our strategic collaborations are based on the ability of Bicycles to address a wide variety of targets. Through collaborations with AstraZeneca, Oxurion, Innovate UK and the Dementia Discovery Fund, we work with companies that have deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients.

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

"Innovative medicine for everyone, everywhere" Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia operates in the diabetes and metabolic disease field. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : http://offres.adocia.com/en

At Alex Therapeutics, we design and develop CE-certified Digital Therapeutics (DTx) products. We’re a pioneer within our field, combining Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with Artificial Intelligence to provide patients with highly personalized and effective care. The Alex Platform allows for the easy development of new products, and we see incredible potential in future verticals such as obesity, depression, oncology, and more. We’re always looking for great partners and co-workers. Please send us an email at partner@alextherapeutics.com to get in touch.

APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product. APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Who we are: atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. Our vision: To heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Our approach: By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients. The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.

To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial. Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages. By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.). For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions. CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.

CUREosity is a multiple international award-winning Med-Tec company located in Düsseldorf, Germany, that is changing rehabilitation by developing innovative therapy concepts. With our vision to revolutionize traditional rehabilitation we develop VR-based therapy applications and games to help people with neurological and mental disabilities. Change the world and become part of a unique collaboration between scientists, medical doctors, therapists, software developers and game designers. Together we develop completely new motion therapy systems - immersive instead of invasive. Impairments we aim to heal include stroke, craniocerebral trauma, MS, cerebral palsy, Parkinson's, paraplegia as well as dementia, depression, anxiety and pain therapy. With CUREO we developed our first smart software solution for innovative VR therapy that can be used immediately in any clinic. Grow with us! Give your daily work a deeper meaning and support us with your talent to help people with neurological and psychological disabilities. You can also benefit from being on board by growing with us personally and professionally, revolutionizing traditional rehabilitation. Became curious? Then follow or contact us on LinkedIn, visit our website and apply at jobs@cureosity.de!

Kynos Therapeutics is poised to bring a new generation of potent first-in-class KMO inhibitors to the market - ready to impact on unmet medical needs. Kynos Therapeutics Ltd. is a Private Limited Company Registered in England and Wales, Company number 12501037

LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA™). Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology and robotics.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Ludocare is to create ways to provide assistance to patients and their families to improve their abilities, autonomy, and quality of life.

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets. Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.

MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.

Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments. By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in old age is inevitable. At Causeway, we believe that physical decline in old age is not inevitable and in indeed may be reversible. To address this, we are developing a range of therapies that treat common MSK diseases that will allow us to remain fit and active into our nineties and beyond. Staying active as we get older also reduces the risk of developing osteoporosis, dementia, diabetes, obesity, cancer and cardiovascular disease. Finding a way to remain fit and active as we age isn’t just a personal imperative but also a global one. By 2050, one in four of us will be over 65 years old, the number of people age over 80 is projected to triple and retirement age to rise to 75-80 years old. As individuals and as a society, we need to find solutions to the problems of ageing. Our goal is to develop therapies that treat the most common MSK diseases, such as osteoarthritis, tendinopathy and lower back pain, re-defining what old age looks and feels like.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx’s first experimental medicine, efgartigimod, is being evaluated in multiple autoimmune diseases, including myasthenia gravis (MG), pemphigus vulgaris (PV), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx is located in Ghent, Belgium, Boston, Massachusetts and Tokyo, Japan.

Oliva is the employee mental wellbeing platform for companies who want to help their people show up feeling their best—and do their best work. By combining proper therapy courses, coaching (the good kind), dedicated support for managers, and mental fitness classes—all led by a curated team of top professionals—Oliva helps employees respond to whatever hurdles life throws at them: big or small, at work and beyond.

We are a team of highly experienced osteopaths, acupuncturists, pilates, sports therapists and biomechanical specialists working across Central London, Liverpool street, Old street, Hoxton, Beckenham and Bromley.

Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis. Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen. Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.

Antag Therapeutics is based on years of collaborative research from the University of Copenhagen with the focus on novel treatments for dietary-related metabolic diseases. The research teams of professors Mette M. Rosenkilde and Jens J. Holst have discovered naturally occurring therapeutic peptides that are being investigated in several human studies.

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital. For more information, please visit www.crescendobiologics.com.

At Dawn Health, we are human-centric digital health pioneers, with an industry leading product development platform. We build beautiful, bespoke & life-changing digital health products to improve the lives of patients around the world living with chronic diseases, specializing in the development of software as medical device (SaMD) and digital therapeutics (DTx). We Code to Save Lives and we work tirelessly everyday to achieve this vision, building digital health products driven by human insights and empathetic design. With a process that, from start to finish, is located in-house and driven by our expert teams, there are no outsourced resources. We build strong partnerships with the industry leaders through our approach and by ongoing collaboration throughout the entire product process, we deliver world class digital health products built at exceptional speed on our cutting edge Dawn Platform. Founded in Denmark in 2016, our international workforce lives by Danish values of exceptional design, globally leading innovative products and a workplace culture that supports employees in their professional and private lives. Our HQ is in Copenhagen and we operate on a global scale to deliver digital health solutions to those that need them.

AFYX Therapeutics is a private biopharmaceutical company focused on innovative approaches to treat mucosal diseases. The Company has developed the Rivelin patch, a breakthrough therapy for the treatment of mucosal diseases. Rivelin is designed to deliver a pharmaceutical drug uni-directionally to a mucosal surface using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface. AFYX's lead Rivelin patch product candidate seeks to treat the auto-immune, inflammatory disease oral lichen planus (OLP) through direct delivery of the drug clobetasol propionate. OLP may appear as lesions in the mouth that may cause burning, pain and other discomfort. OLP is considered an autoimmune disorder and requires regular monitoring given patients have increased risk of developing mouth cancer in the affected areas. No U.S. Food and Drug Administration (FDA) approved treatment exists, with today’s off-label treatment ranging from topical corticosteroids to laser ablation. It is estimated that OLP affects 1% to 2% of the population. Following successful results from a Phase 1b clinical study of the non-drug-loaded Rivelin patch in patients with OLP, AFYX has begun a Phase 2b clinical study of the clobetasol-loaded Rivelin patch in the United States and various countries in Europe. Shareholders include Sofinnova Ventures, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest.

FIRE1 aims to improve patient quality of life, and patient outcomes, while lowering overall healthcare costs.

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.

CardioRenal uses the advanced technologies to develop digital therapeutic solutions.

Mindable Health offers a therapeutic app to overcome anxiety.

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit www.nucleome.com.

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with our leading expertise in GMP NGS-based biosafety testing and characterization services. As innovator companies continue to bring exciting novel therapies to market, there is a critical need for alternative biosafety and characterization strategies. This is especially the case for life-changing cell and gene therapies, as well as novel viral vaccines. Classical testing approaches, such as cell based assays, are often challenging to implement due to high volume requirements, as well as compatibility issues. Biosafety testing and characterization are key regulatory requirements for the release of biologic therapies. Therefore, alternative methods which can address these issues are of intense interest. There is also a drive from across industry and regulators to reduce, and eventually eliminate the use of animal models used in biosafety testing. The genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays From our origins within the Institut Pasteur, PathoQuest is leading the way in expertise for the provision of GMP NGS based biosafety testing. Our expertise is underlined with over 20 peer reviewed publications on NGS applications in biosafety testing; as well as active participation in industry groups such as PDA, ADVTIG, CAACB and EFPIA. PathoQuest are committed to bringing this game-changing genomic approach to biopharmaceutical developers and manufacturers. PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA); and have provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally. Why not get in touch to see how we can help you with your biosafety testing strategy?

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. For more information on Iterum Therapeutics please visit www.iterumtx.com.

SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.

Amal Therapeutics is a Biotechnology company located in 64 av., de la Roseraie, 1205 Geneva, Switzerland.

Sensual4Umassage is where your desires shape an unforgettable experience. Based just outside Farnham in Surrey, we travel within a 50-mile radius to offer you a personalized, deeply connecting experience.

Laura's Touch provides clinical remedial and therapeutic massage therapy, manual lymphatic drainage/post op surgical care and non-surgical body sculpting services based in Hayes, Bromley. Specializing in incorporating and combining the most effective Neuro-Muscular and Myofascial Release techniques, Advanced Deep Tissue and Trigger Point Massage Therapy.

Reflexologie Paris 17 offers holistic massages and reflexology for relaxation, stress relief, and natural healing in a peaceful Paris center.

Orthopred in Wiesloch bietet regenerative Orthopädie mit modernen Therapien für mehr Beweglichkeit und zur Vermeidung unnötiger Operationen.

Therapy Laura provides compassionate, professional therapy services to help individuals improve their mental well-being, build resilience, and navigate life's challenges. Through a supportive and confidential approach, clients receive personalized care for anxiety, stress, menopause anxiety, relationships, trauma, and personal growth, empowering them to achieve lasting emotional health, confidence, and balance at every stage of life.